Dapagliflozin for Inpatient Heart Failure
Protocol: STUDY00005454
Full Title
A multicenter randomized, double-blind, parallel group, placebo-controlled trial to evaluate the effect of in-hospital initiation of dapagliflozin on clinical outcomes in patients with heart failure with reduced ejection fraction who have been stabilized during hospitalization for acute heart failure
Description
Study to assess the effect of dapagliflozin as compared with placebo in patients with heart failure who have been stabilized during hospitalization for acute heart failure. Patients will be followed for a maximum of 2 months.
Compensation: Yes
?
Compensation may include cash, checks, gift cards, debit cards, or incentives like gift baskets, technology items, or merchandise.
Eligibility
1. Currently hospitalized with AHF with symptoms of AHF.
2. LVEF <40% within the past 12 months
3. Elevated NT-proBNP, >1600 pg/ml
4. > 18 years of age
5. eGFR >30
Age Group: Adults
Principal Investigator: JOSEPH IZZO
ClinicalTrials.gov: Open Study
Contact(s)
KELLEY CAROZZOLO (Bilson)
kjc28@buffalo.edu
+1 716-898-5653
Want to Learn More?

Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email ctsiresearch@buffalo.edu and someone will assist you.

Your information will be shared only with the research study team for recruitment purposes and designated CTSI personnel for project quality assurance and will remain confidential. Your information will be stored indefinitely. Should you no longer want this information to be provided in the aforementioned ways, please contact ctsiresearch@buffalo.edu.